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Appendiceal cancer is a rare disease with reported age-adjusted incidence rates 
ranging from 0.12 to 4 cases per 1,000,000, but it presents with a wide range 
of histologic subtypes that carry diff erent prognostic implications [1,2]. Given 
the rarity and heterogeneity of the disease, there is little evidence to support 
best treatment practices [3]. There are many diff erent subtypes of appendiceal 
cancer, and their classifi cation and terminology have been a source of debate 
and confusion in the past [4]. While some epithelial tumors of the appendix 
can behave similarly to those found in colonic primary sites, the majority of 
appendiceal adenocarcinomas are of the mucinous histologic subtype [2]. These 
tumors can produce abundant intraabdominal mucin, and are further defi ned by 
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their diff erentiation level, or grade [4]. Tumor grade has signifi cant implications 
on both clinical predilections and survival in this patient population [4,5]. Low 
grade appendiceal mucinous adenocarcinomas tend to evolve into peritoneal 
metastases rather than distant metastases, but are a distinct entity from low 
grade appendiceal mucinous neoplasms (LAMN), which do not invade beyond 
the lamina propria [4,6]. Here, we will discuss the management of low grade 
mucinous appendiceal adenocarcinomas. 
Many cases of appendiceal adenocarcinoma are discovered incidentally 
on pathologic review of appendectomy specimens resected for presumed acute 
appendicitis, with approximately 1% of appendectomy specimens revealing 
malignancy [7]. While a right hemicolectomy was originally proposed as treat-
ment for appendiceal cancer, the question of whether it is necessary for all 
appendiceal cancers remains unclear [8]. Sugarbaker reviewed a series of 299 
patients with mucinous appendiceal neoplasms, and found patients with low or 
moderately diff erentiated tumors had a low incidence of lymph node positiv-
ity (6%) compared to patients with high grade disease (29%), and concluded 
that hemicolectomy should only be performed for patients with high grade dis-
ease [9]. Similarly, a recent study evaluating patients with non-metastatic low 
grade mucinous appendiceal cancers found that there was no survival benefi t to 
performing hemicolectomy over a margin-negative appendectomy alone [10]. 
However, over 67.2% of these patients underwent colonic resection beyond 
appendectomy, suggesting that while there may be little evidence to support 
the practice of performing a right hemicolectomy, many providers continue to 
perform this practice [10]. 
For patients with metastatic low grade mucinous appendiceal adenocarci-
noma, cytoreductive surgery with or without hyperthermic intraperitoneal chem-
otherapy (HIPEC) is the primary modality in management of the disease [6]. An 
important part of the preoperative workup is cross sectional imaging to determine 
resectability of the intracellular mucin, and to estimate the peritoneal carcinoma-
tosis index (PCI) [6]. For patients who have disease that is deemed resectable, 
cytoreduction with removal of visible gross disease or with residual tumor that is 
no greater than 2 mm thick to allow penetrance of HIPEC [6]. While some small 
retrospective studies show improved survival of cytoreduction with HIPEC over 
cytoreduction alone, there remains some controversy over the utility of HIPEC 
use in patients with this disease [11]. Even with debulking and HIPEC, recurrence 
is frequently seen with reported median disease free survival of 38.1 months [3]. 
However, due to the indolent nature of low grade disease, median 5 year survival 
remains at 75–81% [3]. 
Systemic chemotherapy has also been suggested as an adjunct therapy for 
patients with metastatic low grade mucinous appendiceal adenocarcinoma, es-
pecially in cases deemed to be unresectable [3]. However, some studies have 
shown that systemic chemotherapy use in this particular subset of patients is not 
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associated with improved survival [12,13]. This is hypothesized to be related to 
the indolent nature of low grade disease, as chemotherapy agents tend to target 
disrupting cell replication [3]. While some aspects of best treatment practices of 
metastatic low grade appendiceal mucinous adenocarcinoma remain unclear, it is 
important to note that these patients should all be referred to palliative care within 
eight weeks of diagnosis; this is in accordance to the American Society of Clini-
cal Oncology guidelines released in 2012 regarding integration of palliative care 
with standard oncologic treatment [14]. 
While appendiceal cancers are a rare disease, the incidence is increasing 
[2]. Low grade appendiceal mucinous adenocarcinomas are a unique subtype that 
tends to have a more indolent natural history but is unfortunately often diagnosed 
in late stages [10]. Although there is limited data supporting treatment for this 
disease, surgical resection remains a critical component of management. 
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